Eric Swayze Sells 7,154 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 7,154 shares of Ionis Pharmaceuticals stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $32.84, for a total transaction of $234,937.36. Following the transaction, the executive vice president now directly owns 45,670 shares in the company, valued at approximately $1,499,802.80. This represents a 13.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Eric Swayze also recently made the following trade(s):

• On Tuesday, November 12th, Eric Swayze sold 1,194 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $37.92, for a total value of $45,276.48.

Ionis Pharmaceuticals Stock Performance

NASDAQ IONS opened at $31.43 on Friday. The firm has a market capitalization of $4.96 billion, a P/E ratio of -12.88 and a beta of 0.35. The company has a current ratio of 8.91, a quick ratio of 8.82 and a debt-to-equity ratio of 1.86. The firm’s fifty day moving average price is $35.63 and its two-hundred day moving average price is $41.14. Ionis Pharmaceuticals, Inc. has a 1 year low of $31.40 and a 1 year high of $52.49.

Institutional Investors Weigh In On Ionis Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of IONS. GAMMA Investing LLC grew its holdings in Ionis Pharmaceuticals by 83.9% during the third quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock worth $27,000 after purchasing an additional 303 shares during the period. Itau Unibanco Holding S.A. acquired a new stake in shares of Ionis Pharmaceuticals in the second quarter valued at approximately $37,000. Capital Performance Advisors LLP bought a new position in shares of Ionis Pharmaceuticals during the 3rd quarter worth approximately $40,000. Prospera Private Wealth LLC acquired a new position in shares of Ionis Pharmaceuticals during the 3rd quarter worth approximately $42,000. Finally, Quantbot Technologies LP bought a new stake in Ionis Pharmaceuticals in the 3rd quarter valued at $51,000. 93.86% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on IONS shares. Piper Sandler cut their price target on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $70.00 target price on shares of Ionis Pharmaceuticals in a research note on Wednesday. William Blair reissued an “outperform” rating on shares of Ionis Pharmaceuticals in a research note on Friday, December 20th. Guggenheim cut their price target on Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Wednesday, October 9th. Finally, Wells Fargo & Company decreased their price objective on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $60.65.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.